Adia Nutrition reported a sharp revenue increase to $0.700508 million for the year ended December 31, 2025, up from $0.00638 million in 2024, while posting a net loss of $(0.395464) million. Gross profit improved to $0.19167 million and operating loss was $(0.366492) million driven by total operating expenses of $0.558162 million. The filing does not present a net income per share figure in the cited sections.
Financial Highlights
Total Revenue: $0.700508 million (2025), significant increase from $0.00638 million (2024)Gross Profit: $0.19167 million (2025)Operating Income: $(0.366492) million (2025); total operating expenses were $0.558162 millionNet Income: $(0.395464) million (net loss for the year ended December 31, 2025)Net Income Per Share: Not provided in the cited sections
Business Highlights
Revenue Growth and Mix: Revenue increased to $700.5K in 2025 from $6.4K in 2024, driven by new service and product sales with a notable shift in sales mix toward medical procedures and biologics.Channel Shift: Medical procedures and biologics comprised meaningful portions of 2025 revenue (approximately 35% and 63%, respectively), reducing reliance on supplement sales.Segment Expansion: Expansion of Adia Med and Adia Labs operations with increased biologics sales and higher clinical activity.Operational Investments: Launched clinical services, initiated R&D and clinical trial activities, expanded staffing, and leased equipment to support growth.Forward Outlook: Management expects operating costs in the range of $450K–$750K and anticipates continued revenue growth to help fund operations, while remaining open to seeking external capital if necessary.
Original SEC Filing: Adia Nutrition, Inc. [ ADIA ] – 10-K – Mar. 31, 2026
Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
